When asked about the company's growth prospects, Sherif said Medidata touches almost 50% of all new clinical trials, but currently only has 3% to 4% penetration in the space. That leaves a long road for adoption, he continued.
Cramer said sometimes you don't get a chance to buy low and sell high with high-flying stocks. Sometimes you have to hold your nose and buy high so you can sell even higher.
Know Your IPO
In his "Know Your IPO" segment, Cramer went to the movies with the upcoming IPO of AMC Entertainment, which will be coming public next week under the all-too-obvious ticker, AMC.
Cramer said that AMC Entertainment should not be confused with AMC Networks (AMCX) -- this one is the second-largest movie theater chain in the U.S. with 343 locations totaling 4,950 screens. The company plans to offer 18.4 million shares between $18 and $20, giving it a market cap around $1.8 billion.Cramer said AMC is absolutely worth owning, even up to $23 a share in the aftermarket, because the company is taking control of its own destiny and proving the naysayers wrong time and time again. How can movie theaters compete with the ultimate convenience of Netflix (NFLX)? Innovation. Cramer said. AMC has 34% market share in our nation's top five markets and has the highest margins thanks to higher-than-average ticket prices and concessions. But AMC is not sitting still -- the company is building larger screens to directly take on IMAX (IMAX) and is adding reclining seats and dining options, including seat-side service at some of its locations. This is turning the movies into a must-see destination, said Cramer, and something moviegoers are loving. AMC also plans of sporting a dividend around 4.2%, which is something shareholders will love, said Cramer.